Kymera Therapeutics

13th Annual T-Cell Lymphoma Forum, July 8-10, 2021 Read More >

Inventing New Medicines

Pioneering Targeted Protein Degradation

Celebrating 5 years of passion, precision and purpose...Hear from the team on this significant milestone:

News & Events

07/12/21

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum

Read More
07/06/21

Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Read More

Targeted Protein Degradation

A New Way to Treat Disease

Kymera is a clinical stage biopharmaceutical company developing novel protein degrader therapeutics to treat disease in powerful new ways, which harness the body’s natural protein degradation system to selectively degrade disease causing proteins with the goal of completely removing them from the body. Kymera is driven to invent transformative medicines for a wide variety of diseases where traditional drug modalities have failed to sufficiently unlock the appropriate biological solution.

A Powerful Drug Discovery Engine

Kymera has developed a proprietary targeted protein degradation platform called Pegasus which enables the design of highly selective small molecule protein degraders – heterobifunctional molecules with potent activity against disease-causing proteins. Thanks to our Whole Body E3 Ligase Atlas, Pegasus is expanding the universe of potential disease targets and possible treatments.